We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Nestlé has announced that it will acquire Aimmune Therapeutics for $2.6 billion in a deal that will add Palforzia — the first FDA-approved treatment for patients with peanut allergy — to Nestlé’s pharmaceuticals portfolio. Read More
GlaxoSmithKline failed yesterday to convince an FDA advisory committee that it should be allowed to add study data showing a reduction in mortality to the label of its chronic obstructive pulmonary disease (COPD) drug Trelegy Ellipta. Read More
GlaxoSmithKline and Vir Biotechnology have dosed the first patient in a phase 2/3 clinical trial of their investigational COVID-19 antibody treatment VIR-7831 for early treatment in patients at high risk of hospitalization. Read More
Two COVID-19 vaccine candidates being developed by Chinese pharma companies have already received emergency authorization in China, the country’s National Medical Products Administration (NMPA) revealed. Read More
Johnson & Johnson (J&J) says it will begin a phase 2 trial of its COVID-19 vaccine candidate in Spain, Germany and the Netherlands this week. Read More
Moderna said Friday that it is in talks with Japan’s Ministry of Health, Labor and Welfare to supply the country with at least 40 million doses of its COVID-19 vaccine. Read More
The UK has unveiled a proposal that would empower the Medicines and Healthcare Products Regulatory Agency (MHRA) to temporarily authorize effective COVID-19 vaccines while they are still under review. Read More
The FDA announced late Friday that it has decided to expand its Emergency Use Authorization (EUA) for Gilead Sciences’ remdesivir, allowing its use in patients with mild or moderate COVID-19 infections. Read More